A multi-antigenic epitope subunit vaccine derived from chicken-derived *Riebelella anatipestifer* and its application

A multi-antigen epitope subunit vaccine was prepared by fusing chicken IgY Fc fragments with B-cell epitopes of Riegeria anatipestifer OmpA, OmpH, and GroEL proteins. This solved the problems of narrow protective spectrum and insufficient immunogenicity of existing vaccines, and achieved highly efficient protection against multiple serotypes and safe immunization.

CN123106928APending Publication Date: 2026-11-17JINYU YOUBANG BIOTECHNOLOGY (JIANGSU) CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611592735.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing duck plague Riesella vaccines have a narrow protective spectrum and insufficient protection rate with a single antigen, making it difficult to effectively cover multiple serotypes. Furthermore, inactivated vaccines pose biosafety risks, and monovalent subunit vaccines have limited immunogenicity.

Method used

A multi-antigen epitope subunit vaccine was prepared by using a tandem fusion protein of chicken IgY Fc fragment and B-cell epitopes OmpA, OmpH, and GroEL proteins from Riegeria anatipestifer, through a baculovirus-insect cell expression system. This vaccine enhances the immune response and achieves broad-spectrum protection.

Benefits of technology

It achieves broad-spectrum protection against multiple serotypes of Riedelella anatipestifer, increasing the immune protection rate to 70%~80%, avoiding the risks of live bacteria culture, and enhancing the immune effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106928A_ABST
    Figure CN123106928A_ABST
Patent Text Reader

Abstract

This invention discloses a chicken-derived multi-antigen epitope subunit vaccine for *R. anatidae* and its application, belonging to the field of animal disease vaccine technology. This invention provides a fusion protein composed of a chicken IgY Fc fragment and B-cell epitopes of multiple proteins from *R. anatidae*, the fusion protein comprising 458 amino acids, and the encoding gene optimized using insect cell codons. This invention also provides the gene encoding the fusion protein, biological materials containing the gene, a subunit vaccine containing the fusion protein, and a method for its preparation. The vaccine is prepared using a baculovirus-insect cell expression system with mineral oil as an adjuvant. Animal experiments show that the vaccine provides 70% and 80% protection against challenge with chicken-derived *R. anatidae* serotypes 2 and 10, respectively, and can provide broad-spectrum prevention of infection with different serotypes of *R. anatidae*.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a chicken-derived Riedebrionia duck disease multiantigen epitope subunit vaccine and its application, belonging to the field of animal disease vaccine technology. Background Technology

[0002] Anal ripariasis is a contagious disease caused by *Riemerella anatipestifer* (RA), primarily infecting poultry such as ducklings, goslings, turkeys, and chickens. It is characterized by fibrinous pericarditis, perihepatitis, air sacculitis, and meningitis, causing severe economic losses to waterfowl and the poultry industry. In recent years, there has been an increase in reports of *Riemerella anatipestifer* isolates from chickens, and RA infection in chicken flocks has become a significant problem affecting poultry health.

[0003] There are many serotypes of Riesella anatipestifer, with 21 serotypes (types 1 to 21) reported so far, and there is a lack of cross-protection between the serotypes. Existing commercial vaccines are mainly inactivated vaccines and monovalent subunit vaccines, which have the following technical problems: (1) Inactivated vaccines require the cultivation of a large number of bacteria, which poses a biosafety risk; (2) Monovalent subunit vaccines target only a single antigen, have a narrow spectrum of protection, and are difficult to cover multiple serotypes; (3) The immunogenicity of a single antigen protein is limited, and the protection rate is not high.

[0004] In existing technologies, the outer membrane protein A (OmpA) of *R. anatidae* has been confirmed as a protective antigen, but the immunoprotective rate of OmpA antigen alone is limited. The chaperone protein GroEL is highly conserved among different serotypes of *R. anatidae*, but the protective rate of GroEL alone is only 37%–50%. Therefore, there is still a need in the field for a *R. anatidae* subunit vaccine that can provide broad-spectrum protection, strong immunogenicity, and high protective efficacy. Tandem fusion of B-cell epitopes of multiple conserved antigen proteins, and aided by immunostimulatory sequences, is an effective strategy to solve the above-mentioned technical problems. Summary of the Invention

[0005] The purpose of this invention is to provide a chicken-derived Riedebrion anatipestifer multiantigen epitope subunit vaccine, its preparation method, and its application, so as to solve the technical problems of narrow protection spectrum and insufficient protection rate of single antigen in existing Riedebrion anatipestifer vaccines.

[0006] The first technical solution provided by this invention is a recombinant fusion protein of multiple antigenic epitopes from *R. anatidae*, derived from chicken IgY Fc fragments and B-cell epitopes of *R. anatidae* OmpA, OmpH, and GroEL proteins tandemly fused. OmpA contains three B-cell epitopes (SEQ ID NO. 4-6), OmpH contains three B-cell epitopes (SEQ ID NO. 7-9), and GroEL contains three B-cell epitopes (SEQ ID NO. 10-12). The epitopes are linked to each other and to the IgY Fc fragment via a flexible linker peptide GGGGS. The amino acid sequence of the fusion protein is shown in SEQ ID NO. 1, with a total length of 458 amino acids.

[0007] The second technical solution provided by the present invention is a gene encoding the antigen described in the first technical solution.

[0008] The third technical solution provided by the present invention is a recombinant vector carrying the gene described in the second technical solution.

[0009] In some embodiments, the recombinant vector uses PET series plasmids as expression vectors.

[0010] In some embodiments, the recombinant vector uses pFastBac1 as the expression vector.

[0011] The fourth technical solution provided by the present invention is to express the fusion protein described in the first technical solution, or to contain the gene described in the second technical solution, or to transform a host cell with the recombinant vector described in the third technical solution.

[0012] In some embodiments, the host cell is a microbial cell or an insect cell.

[0013] In some embodiments, the host cell is Escherichia coli.

[0014] The fifth technical solution provided by the present invention is a vaccine, which includes the fusion protein described in the first technical solution.

[0015] In some embodiments, the vaccine further includes adjuvants, such as Freund's adjuvant, aluminum hydroxide adjuvant, CPG adjuvant, etc., which can be used in vaccines.

[0016] The sixth technical solution provided by the present invention is the use of the fusion protein described in the first technical solution, or the gene described in the second technical solution, or the recombinant vector described in the third technical solution, or the host cell described in the fourth technical solution, or the vaccine described in the fifth technical solution in the preparation of a drug for the prevention, mitigation and / or treatment of diseases caused by Riesella anatipestifer.

[0017] In some embodiments, the drug contains a pharmaceutically acceptable carrier or excipient.

[0018] In some embodiments, the pharmaceutically acceptable carrier includes liposomes, microcells, metal particles, or polymer particles.

[0019] In some embodiments, the related diseases caused by Riedelium anatipestifer include Riedelium anatipestiferosis.

[0020] Compared with the prior art, the beneficial effects of the present invention are as follows: (1) Broad-spectrum protection: The three proteins OmpA, OmpH, and GroEL are highly conserved among different strains of Riemerella anatipestifer (cross-strain sequence identity is 98.4%, 93.8%, and 99.8%, respectively). Seven of the nine selected epitopes are 100% conserved in the compared strains, which is expected to cover multiple serotypes. (2) Multi-target synergy: The fusion of three proteins results in a total of nine B-cell epitopes, which target both outer membrane proteins and chaperone proteins, resulting in a more comprehensive immune response. (3) Enhanced immunity: The chicken IgY Fc fragment (CH3-CH4 domain) serves as the N-terminal vector, which can enhance antigen presentation and immune response. (4) Safe and controllable: The baculovirus-insect cell expression system is used, eliminating the risk of live bacteria culture. (5) Clear protective efficacy: Animal experiments show that the fusion protein immunization group has a protection rate of 70% and 80% against challenge of chicken-derived Riemerella anatipestifer type 2 and type 10 strains, respectively. Attached Figure Description

[0021] Figure 1 This is a Bepipred 3.0 prediction map of dominant B-cell epitopes for OmpA, OmpH, and GroEL proteins in *Riebelella anatipestifer*. A: Predicted results for the OmpA dominant B-cell epitope; B: Predicted results for the OmpH dominant B-cell epitope; C: Predicted results for the GroEL dominant B-cell epitope. Each dominant B-cell epitope is highlighted in yellow.

[0022] Figure 2 This is an agarose gel electrophoresis result of the recombinant baculovirus PCR identification in Example 1 of the present invention. M: DNA Marker; Lane 1: rBacmid-RA-F recombinant baculovirus identification band.

[0023] Figure 3 This is an image showing the SDS-PAGE identification results of the IgY Fc-RA-MultiEpi fusion protein in Example 2 of this invention. M: Protein Marker; Lane 1: IgY Fc-RA-MultiEpi fusion protein identification band.

[0024] Figure 4This is a gross necropsy pathological change diagram from the efficacy evaluation test of the IgY Fc-RA-MultiEpi fusion protein vaccine against chicken-derived Riemerella anatipestifer strains 2 and 10 in Example 3 of the present invention. Detailed Implementation

[0025] The preferred embodiments of the present invention are described below. It should be understood that the embodiments are for better explanation of the present invention and are not intended to limit the present invention.

[0026] Raw materials used in the examples: The SF9 and HF insect cells used in the embodiments of this invention were purchased from Thermo Fisher Scientific. The chicken-derived duck plague Riegeria strain YBRA01 (serum type 2, accession number CGMCC No. 37709, deposit address Beijing, China) and strain YBRA02 (serum type 10, accession number CGMCC No. 37710) were isolated and preserved by the applicant's laboratory.

[0027] Example 1: Prediction of multiple antigenic epitopes and design of fusion genes in chicken-derived Riegeria duck plague bacteria B-cell epitope prediction was performed using Bepipred 3.0, a tool for predicting B-cell antigenic epitopes, on the OmpA, OmpH, and GroEL protein sequences of *Riebelella anatipestifer* (GenBank: CP110126.1). The linear epitope score was used, with the top-30% percentile as the threshold and a minimum epitope length of 7 amino acids, excluding signal peptide regions (predicted signal peptides at positions 1-21 of OmpA and OmpH). The prediction results are shown below. Figure 1 As shown, a total of 9 B-cell epitopes were screened: 3 OmpA epitopes (SEQ ID NO. 4~6), 3 OmpH epitopes (SEQ ID NO. 7~9), and 3 GroEL epitopes (SEQ ID NO. 10~12). Information on each B-cell epitope is shown in Table 1.

[0028] To support broad-spectrum protection, multiple sequence alignment (MSA) analysis was performed on the OmpA, OmpH, and GroEL protein sequences of multiple strains of *R. anatidae* published by NCBI. The results showed that the cross-strain sequence identity of the three proteins was 98.4%, 93.8%, and 99.8%, respectively. Of the nine selected epitopes, seven were 100% conserved in the aligned strains (OmpA Epi1, Epi3; OmpH Epi1, Epi3; GroEL Epi1, Epi2, Epi3), and two epitopes showed conservation rates of 83.9% (OmpA Epi2) and 87.5% (OmpH Epi2), indicating that the selected epitopes are highly conserved among different strains of *R. anatidae* and are expected to provide broad-spectrum protection.

[0029] A chicken IgY Fc fragment (CH3-CH4 domain, SEQ ID NO.3, 231aa) was obtained, derived from the Fc segment of the chicken immunoglobulin Y heavy chain (PDB 2W59 Chain B), which has the function of enhancing antigen presentation and immune response. The components were linked together with the flexible linker peptide GGGGS to construct the fusion protein IgY Fc-RA-MultiEpi, with the structure: IgYFc-(GGGGS)-OmpA_1-(GGGGS)-OmpA_2-(GGGGS)-OmpA_3-(GGGGS)-OmpH_1-(GGGGS)-OmpH_2-(GGGGS)-OmpH_3-(GGGGS)-GroEL_1-(GGGGS)-GroEL_2-(GGGGS)-GroEL_3. The fusion protein is 458 amino acids in length (SEQ ID NO.1). The host codons of the fusion protein encoding gene were optimized by *Pseudomonas aeruginosa*. The optimized gene is 1377 bp in length (including the stop codon, SEQ ID NO.2).

[0030] Table 1. B-cell epitope information predicted by Bepipred 3.0

[0031] Example 2: Construction, protein expression, and identification of recombinant baculovirus The fusion gene fragment IgY Fc-RA-MultiEpi (SEQ ID NO.2) obtained in Example 1 was synthesized by Jiangsu Saisofe Biotechnology Co., Ltd., and ligated into the multiple cloning site of the commercial vector pFastBac 1 to construct the recombinant transfer vector pFastBac-RA-F. pFastBac-RA-F was transformed into *E. coli* DH10Bac competent cells, and the fusion gene was integrated into the band granule genome via Tn7 transposition. Positive clones were screened on gentamicin, kanamycin, and tetracycline resistant plates and identified by PCR using the M13 upstream and downstream primers. The M13 upstream primer sequence was 5'-TGTAAAACGACGGCCAGT-3', and the M13 downstream primer sequence was 5'-CAGGAAACAGCTATGACC-3'. The PCR amplification products were identified by agarose gel electrophoresis. The expected amplified fragment size of positive clones was approximately 4500 bp (including the fusion gene insertion fragment), and the results are as follows. Figure 2 As shown, this indicates that the recombinant rod-particle rBacmid-RA-F was successfully constructed.

[0032] The positive recombinant baculovirus rBacmid-RA-F was transfected into SF9 insect cells using liposome transfection, following the instructions for the Cellfectin transfection reagent, to obtain F1 generation recombinant baculovirus rRA-F. The F1 generation virus was then inoculated into SF9 cells for expansion culture, and the F2 generation virus solution was harvested. The virus titer was determined by plaque purification and used for subsequent protein expression.

[0033] The F1 generation recombinant baculovirus rRA-F was inoculated into SF9 insect cells and cultured at 27°C for 4 days. The culture was collected, and the supernatant was obtained by centrifugation to obtain the F2 generation recombinant baculovirus. The F2 generation recombinant baculovirus was inoculated into SF9 cells at an MOI of 5, and the cell culture was collected after culturing at 27°C for 4 days.

[0034] The correctly identified recombinant baculovirus rRA-F was inoculated into HF cells at an MOI of 1-10 for large-scale culture. The culture supernatant was collected by centrifugation, yielding a supernatant containing a large amount of IgY Fc-RA-MultiEpi fusion protein. SDS-PAGE electrophoresis was performed on the supernatant, and the results showed a specific protein band at approximately 50 kDa, consistent with the theoretical molecular weight. Figure 3 ).

[0035] Example 3: Vaccine preparation and evaluation of protective efficacy against challenge The IgY Fc-RA-MultiEpi recombinant protein prepared in Example 2 was added to an inactivation vessel, and BEI (diethyleneimine) was added to a final concentration of 0.5%. The mixture was inactivated at 37°C for 24 hours. After inactivation, sodium thiosulfate was added to neutralize to a final concentration of 2% for 30 minutes. Semi-finished product inspection: (1) Sterility test: Sterility test was performed according to the appendix of the current veterinary pharmacopoeia; (2) Protein content determination: Protein content was determined according to the BCA method; (3) Inactivation test: The inactivated protein solution was inoculated into ordinary broth culture medium and cultured at 37°C for 24 hours. No bacterial growth was considered as qualified for inactivation.

[0036] Preparation of vaccine composition (the liquid components in the following preparation are by volume ratio): (1) Oil phase preparation: Take 95 parts of veterinary white oil and 1 part of aluminum stearate, place them in an oil phase preparation tank and heat to 80°C, then add 5 parts of Span-80 and mix evenly, cool to room temperature for later use; (2) Aqueous phase preparation: Take the inactivated IgY Fc-RA-MultiEpi recombinant protein solution, add Tween-80 to a final concentration of 5%, and mix evenly; (3) Emulsification: Mix the oil phase and aqueous phase at a volume ratio of 2:1, emulsify at 10000 r / min for 5 min, and prepare an oil-in-water vaccine. The recombinant fusion protein content in the vaccine is approximately 100 μg / mL.

[0037] Fifty one-day-old SPF chickens were randomly divided into five groups of ten each: fusion protein immunization group 1, fusion protein immunization group 2, type 2 RA challenge control group, type 10 RA challenge control group, and healthy control group. All chickens in fusion protein immunization groups 1 and 2 were subcutaneously immunized with 0.2 mL of subunit vaccine (each dose containing 20 μg of fusion protein) on day one. Chickens in both challenge control groups were subcutaneously immunized with 0.2 mL of sterile PBS on day one. The healthy control group received neither immunization nor challenge. All five groups were raised in isolation under identical conditions.

[0038] Fourteen days after the initial immunization, a second immunization was administered in the same manner. Fourteen days after the second immunization, chickens in the fusion protein immunization group (types 1 and 2) and the challenge control group (type 2 RA) were challenged with *Rhizobium anatipestifer* strain YBRA01 (serum type 2) at a dose of 1×10⁻⁶. 10 CFU / feather, challenged via intravenous injection; chickens in the fusion protein immunization group 2 and the RA type 10 challenge control group were challenged with chicken-derived duck plague rhesus strain YBRA02 (serum type 10) at a dose of 2 × 10⁻⁶. 10 CFU / feather, challenged via intravenous injection. Observe chickens for 14 consecutive days after challenge, recording morbidity and mortality. Necropsy surviving chickens 14 days after challenge to observe lesions in the pericardium, liver, air sacs, and brain. Infectious serositis in chickens is diagnosed if any of the following criteria are met: (1) death; (2) observation of obvious clinical symptoms (significant depression, loss of appetite, paralysis, or joint swelling, etc.); (3) observation of obvious organ pathological changes during necropsy (pericarditis, perihepatitis, peritonitis, or purulent discharge from the joint cavity, etc.).

[0039] The results of the protection efficacy against viral infection are shown in Table 2 and Figure 4 As shown, the fusion protein-immunized chickens exhibited 70% and 80% protective efficacy against challenges from chicken-derived RA type 2 and RA type 10 strains, respectively; none of the 10 healthy control chickens developed the disease. These results demonstrate that the IgY Fc-RA-MultiEpi fusion protein subunit vaccine of this invention has clear protective efficacy against challenges from chicken-derived *Riebrio anatidae* strains YBRA01 (type 2) and YBRA02 (type 10).

[0040] Table 2 Results of protection efficacy against viral infection

[0041] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.

Claims

1. A fusion protein, characterized in that, The amino acid sequence of the fusion protein is shown in SEQ ID NO.

1.

2. A gene encoding the fusion protein of claim 1.

3. A recombinant vector carrying the gene of claim 2.

4. The recombinant vector according to claim 3, characterized in that, The recombinant vector uses PET series plasmids or the vector pFastBac 1 as the expression vector.

5. Expressing the fusion protein of claim 1, or containing the gene of claim 2, or transforming a host cell with the recombinant vector of claim 3.

6. The host cell according to claim 5, characterized in that, The host cell is a microbial cell or an insect cell.

7. A vaccine, characterized in that, The vaccine comprises the fusion protein as described in claim 1.

8. The vaccine according to claim 7, characterized in that, The vaccine also includes adjuvants, including Freund's adjuvant, aluminum hydroxide adjuvant, and CPG adjuvant.

9. The use of the fusion protein of claim 1, or the gene of claim 2, or the recombinant vector of any one of claims 3-4, or the host cell of any one of claims 5-6, or the vaccine of any one of claims 7-8 in the preparation of a medicament for the prevention, mitigation and / or treatment of diseases caused by *Riebelella anatipestifer*.

10. The application according to claim 9, characterized in that, The diseases caused by Riedelium anatipestifer include Riedelium anatipestiferosis.